CEFIXIME
Cefixime for oral suspension is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections Otitis Media Pharyngitis and Tonsillitis Acute Exacerbations of Chronic Bronchitis Uncomplicated Gonorrhea (cervical/urethral) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs, cefixime...
Details
- Status
- Prescription
- First Approved
- 2015-04-14
- Routes
- ORAL
- Dosage Forms
- CAPSULE, FOR SUSPENSION, TABLET
CEFIXIME Approval History
What CEFIXIME Treats
8 FDA approvalsOriginally approved for its first indication in 2015 . Covers 8 distinct patient populations.
- Other (8)
Other
(8 approvals)Clinical Trial Registry
9 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05294588 | 21-0498 DMID 21-0018, U01AI162457-01 | Ph 2 | completed | Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae |
| NCT04349826 ACT-South Asia | 25NP | Ph 4 | completed | The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) |
| NCT06090565 | 9937 | Ph 4 | completed | Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea |
| NCT03840811 results posted | 09-0106 | Ph 1 | completed | Experimental Human Infection With Neisseria Gonorrhoeae |
| NCT00786669 VITAC | VITAC | Ph 1 | completed | A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors |
| NCT01595529 results posted | 09-0103 | Ph 2 | completed | The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children" |
| NCT01949363 | 12-0025 HHSN272201500007I | Ph 1 | completed | The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study |
| NCT02708992 | 15-0031 HHSN272201500006I | Ph 1 | completed | Cefixime / Azithromycin pK Study |
| NCT01072136 results posted | 07-0082 | Ph 3 | terminated | Empiric Therapy of Mucopurulent Cervicitis (MPC) |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CEFIXIME FDA Label Details
Indications & Usage
FDA Label (PDF)Cefixime for oral suspension is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections Otitis Media Pharyngitis and Tonsillitis Acute Exacerbations of Chronic Bronchitis Uncomplicated Gonorrhea (cervical/urethral) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs, cefixime for oral suspension should be used only to treat infections that are proven or strongly suspected t...
Looking for the branded version?
SUPRAX
Full clinical data, patents, trials, and competitive landscape for cefixime.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.